Physiomics Regulatory News (PYC)

10 November 2022

Physiomics plc

("Physiomics") or ("the Company")

Contract award

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Ankyra Therapeutics ("Ankyra"). Building on the work that was announced in March this year, this contract extension is expected to complete in the first quarter of 2023.

Ankyra is a Boston-based biotech company focused on improving both the safety and efficacy of cancer treatment by using their proprietary anchored immunotherapy platform. Ankyra announced a successful US$45 million Series B funding round a year ago to finance its lead molecule ANK-101 through Phase 1 clinical trials and has an emerging pipeline of additional immunotherapy-based programs. Physiomics is supporting Ankyra with the modelling and simulation of ANK-101 in immune-oncology settings in support of its early development and clinical translation.

Physiomics CEO, Dr Jim Millen, commented: "We are delighted to continue supporting Ankyra Therapeutics for the development of this exciting new molecule ANK-101 through the use of modelling and simulation."

Enquiries:

Physiomics plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.